Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from shigatoxemia

Infection and Immunity

Volumn 73, Issue 10, 2005, Pages 6523-6529

  Marcato, Paola ^a   Griener, Thomas P ^b   Mulvey, George L ^b   Armstrong, Glen D ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Health Sciences Centre Calgary   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; ENDOTOXIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; NEUTRALIZING ANTIBODY; RECOMBINANT SHIGA TOXIN 2B; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEROTYPE; SHIGATOXEMIA; TOXEMIA;

ANIMALS; ENDOTOXEMIA; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; ESCHERICHIA COLI VACCINES; FEMALE; HEMOCYANIN; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PROTEIN SUBUNITS; SHIGA-LIKE TOXIN II; VACCINES, CONJUGATE;

EID: 25444471025     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.10.6523-6529.2005     Document Type: Article

References (51)

1. Acheson, D. W., S. A. De Breucker, M. Jacewicz, L. L. Lincicome, A. Donohue-Rolfe, A. V. Kane, and G. T. Keusch. 1995. Expression and purification of Shiga-like toxin II B subunits. Infect. Immun. 63:301-308.
2. Acheson, D. W. K., M. M. Levine, J. B. Kaper, and G. T. Keusch. 1996. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64:355-357.
3. Acheson, D. W. K., R. Moore, S. De Breucker, L. Lincicome, M. Jacewicz, E. Skutelsky, and G. T. Keusch. 1996. Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect. Immun. 64:3294-3300.
4. Armstrong, G. D., P. N. McLaine, and P. C. Rowe. 1998. Clinical trials of Synsorb-Pk in preventing hemolytic-uremic syndrome, p. 374-384. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, D.C.
5. Boyd, B., S. Richardson, and J. Gariépy. 1991. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter the action of the toxin. Infect. Immun. 59:750-757.
6. Butterton, J. R., E. T. Ryan, D. W. Acheson, and S. B. Calderwood. 1997. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect. Immun. 65:2127-2135.
7. Byun, Y., M. Ohmura, K. Fujihashi, S. Yamamoto, J. R. McGhee, S. Udaka, H. Kiyono, Y. Takeda, T. Kohsaka, and Y. Yuki. 2001. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine 19:2061-2070.
8. Cleary, T. G. 2004. The role of Shiga-toxin-producing Escherichia coli in hemorrhagic colitis and hemolytic uremic syndrome. Semin. Pediatr. Infect. Dis. 15:260-265.
9. Conlan, J. W., R. KuoLee, A. Webb, A. D. Cox, and M. B. Perry. 2000. Oral immunization of mice with a glycoconjugate vaccine containing the O157 antigen of Escherichia coli O157:H7 admixed with cholera toxin fails to elicit protection against subsequent colonization by the pathogen. Can. J. Microbiol. 46:283-290.
10. Conlan, J. W., R. KuoLee, A. Webb, and M. B. Perry. 1999. Salmonella landau as a live vaccine against Escherichia coli O157:H7 investigated in a mouse model of intestinal colonization. Can. J. Microbiol. 45:723-731.
11. Endo, Y., K. Tsurugi, T. Yutsudo, Y. Takeda, T. Ogasawara, and K. Igarashi. 1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 171:45-50.
12. Fraser, M. E., M. M. Chernaia, Y. V. Kozlov, and M. N. James. 1994. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1:59-64.
13. Fraser, M. E., M. Fujinaga, M. M. Cherney, A. R. Melton-Celsa, E. M. Twiddy, A. D. O'Brien, and M. N. James. 2004. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 279:27511-27517.
14. Gordon, V. M., S. C. Whipp, H. W. Moon, A. D. O'Brien, and J. E. Samuel. 1992. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine. Infect. Immun. 60:485-490.
15. Harris, J. R., and J. Markl. 1999. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 30:597-623.
16. Hashimoto, H., K. Mizukoshi, M. Nishi, T. Kawakita, S. Hasui, Y. Kato, Y. Ueno, R. Takeya, N. Okuda, and T. Takeda. 1999. Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producing Escherichia coli O118:H2 at a junior high school in Japan. Pediatrics 103:E2.
17. Havelaar, A. H., M. J. Nauta, and J. T. Jansen. 2004. Fine-tuning food safety objectives and risk assessment. Int. J. Food Microbiol. 93:11-29.
18. Horne, C., B. A. Vallance, W. Deng, and B. B. Finlay. 2002. Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines. Expert Rev. Vaccines 1:483-493.
19. Hurley, B. P., C. M. Thorpe, and D. W. K. Acheson. 2001. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect. Immun. 69:6148-6155.
20. Hussein, H. S., and S. T. Omaye. 2003. Introduction to the food safety concerns of verotoxin-producing Escherichia coli. Exp. Biol. Med. (Maywood). 228:331-332.
21. Hussein, H. S., and T. Sakuma. 2005. Prevalence of Shiga toxin-producing Escherichia coli in dairy cattle and their products. J. Dairy Sci. 88:450-465.
22. Jacewicz, M., H. Clausen, E. Nudelman, A. Donohue-Rolfe, and G. T. Keusch. 1986. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J. Exp. Med. 163:1391-1404.
23. Karmali, M. A. 2004. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol. Biotechnol. 26:117-122.
24. Kleanthous, H., H. R. Smith, S. M. Scotland, R. J. Gross, B. Rowe, C. M. Taylor, and D. V. Milford. 1990. Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2. Microbiological aspects. Arch. Dis. Child. 65:722-727.
25. Konadu, E., A. Donohue-Rolfe, S. B. Calderwood, V. Pozsgay, J. Shiloach, J. B. Robbins, and S. C. Szu. 1999. Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infect. Immun. 67:6191-6193.
26. Konadu, E., J. B. Robbins, J. Shiloach, D. A. Bryla, and S. C. Szu. 1994. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect. Immun. 62:5048-5054.
27. Konadu, E. Y., J. C. Parke, Jr., H. T. Tran, D. A. Bryla, J. B. Robbins, and S. C. Szu. 1998. Investigational vaccine for Escherichia coli O157: phase 1 study of 0157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J. Infect. Dis. 177:383-387.
28. Lingwood, C. A. 1993. Verotoxins and their glycolipid receptors. Adv. Lipid Res. 25:189-211.
29. Lingwood, C. A. 1996. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4:147-153.
30. Marcato, P., G. Mulvey, and G. D. Armstrong. 2002. Cloned Shiga toxin 2 B subunit induces apoptosis in Ramos Burkitt's lymphoma B cells. Infect. Immun. 70:1279-1286.
31. Marcato, P., G. Mulvey, and G. D. Armstrong. 2003. Cloned Shiga toxin 2 B subunit induces apoptosis in Ramos Burkitt's lymphoma B cells. Infect. Immun. 71:4828.
32. Marcato, P., G. Mulvey, R. J. Read, K. Vander Helm, P. N. Nation, and G. D. Armstrong. 2001. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J. Infect. Dis. 183:435-443.
33. Meng, J., and M. P. Doyle. 1997. Emerging issues in microbiological food safety. Annu. Rev. Nutr. 17:255-275.
34. Mulvey, G., R. Vanmaele, M. Mrazek, M. Cahill, and G. D. Armstrong. 1998. Affinity purification of Shiga-toxin I and Shiga-like toxin II. J. Microbiol. Methods. 32:247-252.
35. Mulvey, G. L., P. Marcato, P. I. Kitov, J. Sadowska, D. R. Bundle, and G. D. Armstrong. 2003. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J. Infect. Dis. 187:640-649.
36. Musselli, C., P. O. Livingston, and G. Ragupathi. 2001. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J. Cancer Res. Clin. Oncol. 127:R20-R26.
37. Nishikawa, K., K. Matsuoka, E. Kita, N. Okabe, M. Mizuguchi, K. Hino, S. Miyazawa, C. Yamasaki, J. Aoki, S. Takashima, Y. Yamakawa, M. Nishijima, D. Terunuma, H. Kuzuhara, and Y. Natori. 2002. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. USA 99:7669-7674.
38. O'Brien, A. D., V. L. Tesh, A. Donohue-Rolfe, M. P. Jackson, S. Olsnes, K. Sandvig, A. A. Lindberg, and G. T. Keusch. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180:65-94.
39. Ostroff, S. M., P. I. Tarr, M. A. Neill, J. H. Lewis, N. Hargrett-Bean, and J. M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 160:994-998.
40. Reisbig, R., S. Olsnes, and K. Eiklid. 1981. The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60 S ribosomal subunit. J. Biol. Chem. 256:8739-8744.
41. Scotland, S. M., G. A. Willshaw, H. R. Smith, and B. Rowe. 1987. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol. Infect. 99:613-624.
42. Stein, P. E., A. Boodhoo, G. J. Tyrrell, J. L. Brunton, and R. J. Read. 1992. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 355:748-750.
43. Strockbine, N. A., L. R. M. Marques, J. W. Newland, H. W. Smith, R. K. Holmes, and A. D. O'Brien. 1986. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 53:135-140.
44. Tana, S. Watarai, E. Isogai, and K. Oguma. 2003. Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes. Lett. Appl. Microbiol. 36:135-139.
45. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin- producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
46. te Loo, D. M., L. A. Monnens, T. J. van der Velden, M. A. Vermeer, F. Preyers, P. N. Demacker, L. P. van den Heuvel, and V. W. van Hinsbergh. 2000. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 95:3396-3402.
47. te Loo, D. M., V. W. van Hinsbergh, L. P. van den Heuvel, and L. A. Monnens. 2001. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J. Am. Soc. Nephrol. 12:800-806.
48. Theilacker, C., F. T. Coleman, S. Mueschenborn, N. Llosa, M. Grout, and G. B. Pier. 2003. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect. Immun. 71:3875-3884.
49. Tzipori, S., A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926-941.
50. Uchida, T. 2003. STX-liposome conjugates as candidate vaccines. Drugs Today 39:673-693.
51. Wang, Z. G., L. J. Williams, X. F. Zhang, A. Zatorski, V. Kudryashov, G. Ragupathi, M. Spassova, W. Bornmann, S. F. Slovin, H. I. Scher, P. O. Livingston, K. O. Lloyd, and S. J. Danishefsky. 2000. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc. Natl. Acad. Sci. USA 97:2719-2724.